NICE rejects Novartis' Aimovig on data 'uncertainty' despite migraine benefits
admin 26th September 2019 Uncategorised 0Patient advocates celebrated the approval of Novartis’ migraine prevention drug Aimovig last year, but now England’s cost watchdog has ruled the drug’s benefits don’t warrant its costs. In a final appraisal, the National Institute of Health and Care Excellence ruled that data supporting the drug are insufficient
read more